Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - glecaprevir, quantity: 100 mg; pibrentasvir, quantity: 40 mg - tablet, film coated - excipient ingredients: propylene glycol monocaprylate; tocofersolan; croscarmellose sodium; sodium stearylfumarate; copovidone; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; hypromellose; iron oxide red; macrogol 3350 - maviret is indicated for the treatment of adult and paediatric patients 3 years and older with chronic hepatitis c virus (hcv) genotype (gt) 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis. this includes patients with hcv gt1 infection who were previously treated with either a regimen of an ns5a inhibitor or with an ns3/4a protease inhibitor but not both classes of inhibitors (see 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - phenylephrine hydrochloride, quantity: 1.2 mg/ml; prednisolone acetate, quantity: 10 mg/ml - eye drops, suspension - excipient ingredients: benzalkonium chloride; sodium metabisulfite; sodium citrate dihydrate; sodium chloride; boric acid; hypromellose; disodium edetate; phenazone; polysorbate 80; purified water; hydrochloric acid; sodium hydroxide - severe inflammation (non-infectious) of the eye, such as acute iritis, iridocyclitis, scleritis, episcleritis, uveitis, resistant ocular allergy and inflammation following surgery (where no infectious aetiology is suspected), particularly where unusually rapid control of the inflammation is required.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - timolol maleate, quantity: 6.8 mg/ml (equivalent: timolol, qty 5 mg/ml); bimatoprost, quantity: 300 microgram/ml - eye drops, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; hydrochloric acid; citric acid monohydrate; purified water; sodium chloride; sodium hydroxide - ganfort pf 0.3/5 eye drops are indicated for the reduction of intraocular pressure (iop) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to monotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - ketorolac trometamol, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: sodium chloride; disodium edetate; benzalkonium chloride; octoxinol 40; sodium hydroxide; hydrochloric acid; purified water - acular eye drops are indicated for the short term (2-4 weeks) relief of symptoms of seasonal allergic conjunctivitis. acular eye drops are also indicated for the short term (2-4 weeks) prophylaxis and reduction in inflammation in patients undergoing cataract extraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - ofloxacin, quantity: 3 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium chloride; hydrochloric acid; sodium hydroxide; purified water - the treatment of severe bacterial conjunctivitis caused by ofloxacin sensitive organisms in adults. indications as approved 2nd december 1997: ocuflox eye drops are indicated for the treatment of corneal ulcers (bacterial keratitis) and severe bacterial conjunctivitis caused by ofloxacin-sensitive organisms.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - gentamicin sulfate, quantity: 3 mg/ml (equivalent: gentamicin, qty 3 mg/ml) - eye drops, solution - excipient ingredients: polyvinyl alcohol; dibasic sodium phosphate heptahydrate; sodium chloride; disodium edetate; benzalkonium chloride; sodium hydroxide; purified water; hydrochloric acid - gentopic eye drops are indicated in the topical treatment of infections of the external eye and its adnexa caused by susceptible bacteria. such infections include conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivits, acute meibomianitis and dacryocystitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - fluorometholone, quantity: 1 mg/ml - eye drops, suspension - excipient ingredients: benzalkonium chloride; disodium edetate; sodium chloride; monobasic sodium phosphate; dibasic sodium phosphate heptahydrate; polysorbate 80; sodium hydroxide; purified water; polyvinyl alcohol - indications as at 23 oct 1995 : for steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - 37685 - bag, medical device, reusable - the abbvie carrying accessories are designed to carry a cadd-legacy? 1400 pump. the abbvie carrying accessories are intended for single patient use only.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - 11677 - enteral feeding kit - the abbvie j is intended to provide long-term enteral access for administration of medication to the small intestine. the abbvie j is indicated for the administration of the medication duodopa (levodopa/carbidopa) intestinal gel.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - 35419 - tube, feeding, gastrostomy - the abbvie peg is intended to provide long-term enteral access for administration of medication to the small intestine when used in conjunction with the abbvie j intestinal tube. as needed, enteral nutrition may be administered directly to the stomach in parallel with medication delivery to the intestine. the abbvie peg is indicated for the administration of the medication duodopa (levodopa/carbidopa) intestinal gel.